PD1/PD-L1 Axis in Uro-oncology.
Checkpoint inhibition
PD-L1
bladder cancer
kidney cancer
penile
cancer
prostate cancer
testicular germ cell tumors
Journal
Current drug targets
ISSN: 1873-5592
Titre abrégé: Curr Drug Targets
Pays: United Arab Emirates
ID NLM: 100960531
Informations de publication
Date de publication:
2020
2020
Historique:
received:
10
01
2020
revised:
12
02
2020
accepted:
24
02
2020
pubmed:
28
3
2020
medline:
22
9
2021
entrez:
28
3
2020
Statut:
ppublish
Résumé
The immune system is important to control tumor development and progression in humans. However, tumor cells and cells of the tumor microenvironment can induce immune escape mechanisms including activation of immune checkpoints such as PD-1/PD-L1. Based on this knowledge, new immune therapies, including PD-1 and PD-L1 inhibition, have been developed and are already recommended as a standard treatment in metastatic bladder and kidney cancer patients. In addition to its role as a therapeutic target, PD-L1 seems to be a prognostic parameter although data are controversial. Only little is known about signaling pathways inducing PD-L1 expression in tumor cells on one hand and about its functional role for tumor cells itself. However, the understanding of the complex biological function of PD-L1 will improve therapeutic options in urological malignancies. This review is giving an overview of the current knowledge concerning the PD-1/PD-L1 axis in urological tumors including bladder, kidney, prostate, testicular and penile cancer.
Identifiants
pubmed: 32213156
pii: CDT-EPUB-105491
doi: 10.2174/1389450121666200326123700
doi:
Substances chimiques
B7-H1 Antigen
0
Immune Checkpoint Inhibitors
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1293-1300Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.